However, patients with high-risk genetic subtypes, such as the BCR-ABL1 translocation and KMT2A-rearrangements, and relapsed B-ALL have a significantly inferior response to standard treatments [186,187]. This evidence concerns the gene ABL1 and acute lymphoblastic leukemia.